SecBot SecBot
8-K ·Filed May 6, 2026

LXRX

LEXICON PHARMACEUTICALS, INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001062822-26-000094
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight • Neutral

The refinancing removes near-term liquidity concerns but adds high-interest debt (9.85% floor). Monitor progress of the SONATA-HCM Phase 3 trial (sotagliflozin) as it triggers additional tranche availability and potential interest-only extensions. The warrants are modestly dilutive. No changes to revenue or earnings guidance.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.68
T+0 close · May 6, 2026 · via day close
Latest settled
+38.69%
T+60 · $2.33
Vs SPY
+34.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $1.68entry
  2. T+1 · 6mo ago 0.00%α −0.83% · $1.68
  3. T+5 · 6mo ago +45.24%α +43.73% · $2.44
  4. T+20 · 6mo ago +10.12%α +6.98% · $1.85
  5. T+60 · 4mo ago +38.69%α +34.86% · $2.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lexicon Pharmaceuticals entered into a $100 million loan facility with Hercules Capital, with $55 million funded at closing to repay existing debt. The facility provides non-dilutive capital with an 18-month interest-only period (extendable to 30 months upon milestones) and matures in May 2030. Warrants for 691,823 shares were issued to Hercules, representing modest dilution.

Key Financial Metrics

Deal Value
$100.0M
Deal Type
credit_facility

Key Facts

  • Loan facility of up to $100 million from Hercules Capital, $55 million funded at closing
  • Funds used to repay existing Oxford Finance loan
  • Interest rate: prime rate + 3.10%, floor 9.85%
  • Interest-only period: 18 months, extendable to 30 months upon clinical/regulatory milestones
  • Warrants issued: 691,823 shares initially (2% of funded amount at $1.59 exercise price), additional warrants for future tranches
  • Maturity date: May 4, 2030
  • Covenants include minimum cash (from June 2027) and minimum revenue if second/third tranches drawn

Financial Impact

Up to $100 million in new debt, $55 million drawn immediately; warrants represent ~0.5% dilution based on current shares outstanding (estimated ~140M)

debtcashdilution

Risk Factors

  • High interest rate (prime+3.1%, floor 9.85%) increases financial costs
  • Covenants include minimum cash and revenue requirements that could restrict operations
  • Warrant dilution if exercised (though small)
  • Failure to achieve clinical milestones limits access to remaining tranches

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001062822-26-000094
Document: pressrelease05-06x2026.htm0001062822-26-000094
Document: 0001062822-26-000094-index-headers.html0001062822-26-000094
Document: 0001062822-26-000094-index.html0001062822-26-000094
Document: 0001062822-26-000094.txt0001062822-26-000094

Track record

16 reports on LXRX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
  5. Aug 6, 202614w ago 8-K Neutral 5/10 No price data
  6. Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
  7. Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
  9. May 6, 202627w ago 8-K Neutral 4/10 Viewing Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
  10. Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026